The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Open accessAbstract
BACKGROUND: Apolipoprotein C-III (APOC3) is a key regulator of plasma triglyceride levels. Elevated triglyceride levels are associated with a risk of adverse cardiovascular events and pancreatitis. ISIS 304801 is a second-generation antisense inhibitor of APOC3 synthesis. METHODS: We conducted a randomized, double-blind, placebo-controlled, dose-ranging, phase 2 study to evaluate ISIS 304801 in untreated patients with fasting triglyceride levels between 350 mg per deciliter (4.0 mmol per liter) and 2000 mg per deciliter (22.6 mmol per liter) (ISIS 304801 monotherapy cohort), as well as in patients receiving stable fibrate therapy who had fasting triglyceride levels between 225 mg per deciliter (2.5 mmol per liter) and 2000 mg per deciliter (ISIS 304801-fibrate cohort). Eligible patients were randomly assigned to receive either ISIS 304801, at doses ranging from 100 to 300 mg, or placebo, once weekly for 13 weeks. The primary outcome was the percentage change in APOC3 level from baseline. RESULTS: A total of 57 patients were treated in the ISIS 304801 monotherapy cohort (41 received active agent, and 16 received placebo), and 28 patients were treated in the ISIS 304801-fibrate cohort (20 received active agent, and 8 received placebo). The mean (±SD) baseline triglyceride levels in the two cohorts were 581±291 mg per deciliter (6.6±3.3 mmol per liter) and 376±188 mg per deciliter (4.2±2.1 mmol per liter), respectively. Treatment with ISIS 304801 resulted in dose-dependent and prolonged decreases in plasma APOC3 levels when the drug was administered as a single agent (decreases of 40.0±32.0% in the 100-mg group, 63.8±22.3% in the 200-mg group, and 79.6±9.3% in the 300-mg group, vs. an increase of 4.2±41.7% in the placebo group) and when it was administered as an add-on to fibrates (decreases of 60.2±12.5% in the 200-mg group and 70.9±13.0% in the 300-mg group, vs. a decrease of 2.2±25.2% in the placebo group). Concordant reductions of 31.3 to 70.9% were observed in triglyceride levels. No safety concerns were identified in this short-term study. CONCLUSIONS: We found that treatment with ISIS 304801 was associated with significant lowering of triglyceride levels, among patients with a broad range of baseline levels, through selective antisense inhibition of APOC3 synthesis. (Funded by Isis Pharmaceuticals; ClinicalTrials.gov number, NCT01529424.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a randomized, placebo-controlled, double-blind phase 2 trial of 57 patients with elevated triglycerides, volanesorsen reduced ApoC-III by up to − 80% and triglycerides by − 71% [175].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [175]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen is an antisense oligonucleotide that targets APOC3 messenger RNA (mRNA) and reduces plasma apolipoprotein C-III levels, as well as the degree of chylomicronemia and plasma triglyceride levels.”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen (previously known as ISIS-APOC-III RX ) is a second-generation ASO developed to inhibit apoCIII”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [170]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen, a second-generation antisense oligonucleotide (ASO) targeting hepatic APOC3 mRNA, has shown the capacity to lower TG by up to 77% in patients with Familial chylomicronemia syndrome (FCS) [114]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several miRNAs and antisense oligonucleotides (ASOs) are currently under investigation in clinical trials for various diseases (Kanasty et al., 2013;van Rooij and Kauppinen, 2014;Gaudet et al., 2015).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Gaudet et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Several novel therapies that potently reduce triglyceride levels are currently in development.[6][7][8]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [8]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The agent has been approved in the European Union and the United Kingdom for the treatment of familial chylomicronemia syndrome and in Brazil for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. 23-25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredIn the citing paper
“In a Phase 2 trial of volanesorsen, 300 mg given weekly to HTG patients (NCT01529424), TG levels were reduced by 80%.68”
From Clinical review on triglycerides (2020) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Flagged first, then by citations
1 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Brunzell JD, 1973, Trans Assoc Am Physicians, 86, 245
Cited by
Sorted by citations
Items 301–400 of 530
Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia
Guan, Y., Hou, X., Tian, P., Ren, L., Tang, Y., Song, A., Zhao, J., Gao, L., & Song, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.646185 · Cited by 14
Multifactorial chylomicronemia syndrome
Chait, A. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000846 · Cited by 17
Marmontel, O., Filippo, M. D., Marçais, C., Nony, S., Dumoux, M., Dancer, M. S., Caussy, C., Charrière, S., & Moulin, P. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.07.030 · Cited by 15
ANGPTL3 serum concentration and rare genetic variants in Finnish population
Tikka, A., Metso, J., & Jauhiainen, M. (2017) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2017.1379608 · Cited by 14
The Role of Antisense Therapies Targeting Lipoprotein(a)
Plakogiannis, R., Sorbera, M. A., Fischetti, B., & Chen, M. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001045 · Cited by 14
Endothelial ARHGEF26 is an angiogenic factor promoting VEGF signalling
Zhu, Q. M., MacDonald, B. T., Mizoguchi, T., Chaffin, M. D., Leed, A., Arduini, A., Małolepsza, E., Lage, K., Kaushik, V. K., Kathiresan, S., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab344 · Cited by 14
Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 14
Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent nephropathy
Attie, A., Schueler, K., Keller, M. P., Mitok, K. A., Simonett, S. P., Hudkins, K. L., Mehrotra, K., Graham, M. J., Lee, R. G., & Alpers, C. E. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00592-8 · Cited by 14
Self-citationRecent Apolipoprotein CIII trials
Tramontano, D., Bini, S., D’Erasmo, L., & Arca, M. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000849 · Cited by 14
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease
Tsimikas, S. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01345-4 · Cited by 16
Drug Discovery for Coronary Artery Disease
Wan, Q., Qian, S., Yonghu, H., Zhang, Y., Peng, Z., Li, Q., Shu, B., Zhu, L., & Wang, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_8 · Cited by 13
Marston, N. A., Bergmark, B. A., Alexander, V. J., Karwatowska‐Prokopczuk, E., Kang, Y. M., Moura, F. A., Prohaska, T. A., Zimerman, A., Zhang, S. M., Murphy, S. A., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.03.003 · Cited by 13
Self-citationThe year in cardiology 2015: prevention
Chapman, M. J., Blankenberg, S., & Landmesser, U. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv721 · Cited by 13
Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk
Farnier, M. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0743-8 · Cited by 14
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia
Larouche, M., Khoury, É., Brisson, D., & Gaudet, D. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01179-y · Cited by 14
Self-citationIs hypertriglyceridemia atherogenic?
Roubille, F., Sultan, A., Huet, F., Leclercq, F., Macia, J., Gervasoni, R., Delseny, D., Akodad, M., & Roubille, C. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.08.009 · Cited by 13
Davis, S. R., Azene, Z. N., Tonkin, A. M., Woods, R. L., McNeil, J. J., & Islam, R. M. (2024) · Climacteric · doi:10.1080/13697137.2024.2310530 · Cited by 12
Masson, W., Lobo, M., Nogueira, J. P., Corral, P., Barbagelata, L., & Siniawski, D. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09893-x · Cited by 12
Rosenson, R. S., & Köenig, W. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6642-9 · Cited by 12
Proprotein convertase subtilisin/kexin type 9
Stoekenbroek, R. M., & Kastelein, J. J. P. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000517 · Cited by 14
Self-citationAfanasieva, O. I., Владиславович, Е. М., & Pokrovsky, S. N. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-8-99-109 · Cited by 15
Morze, J., Koch, M., Aroner, S. A., Budoff, M. J., McClelland, R. L., Mukamal, K. J., & Jensen, M. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113522 · Cited by 12
Using human genetics to predict the effects and side-effects of drugs
Stender, S., & Tybjærg‐Hansen, A. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000280 · Cited by 13
Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events
Lee, S., & Cannon, C. P. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0997-4 · Cited by 12
van Capelleveen, J. C., Lee, S. R., Verbeek, R., Kastelein, J. J. P., Wareham, N. J., Stroes, E. S. G., Hovingh, G. K., Khaw, K., Boekholdt, S. M., Witztum, J. L., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.08.010 · Cited by 12
Self-citationThe Future of Lipid-Lowering Therapy
Zwol, W. H.-V., Rimbert, A., & Kuivenhoven, J. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071085 · Cited by 12
Triglyceride‐rich lipoprotein metabolism in women: roles of apoC‐ II and apoC‐ III
Ooi, E. M. M., Chan, D. C., Hodson, L., Adiels, M., Borén, J., Karpe, F., Fielding, B. A., Watts, G. F., & Barrett, P. H. R. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12657 · Cited by 12
Hypertriglyceridemia Associated With Abdominal Obesity
Carpentier, A. C. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306412 · Cited by 12
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01153-8 · Cited by 12
Ganda, O. P. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000694 · Cited by 11
Lightbourne, M., Wolska, A. T., Abel, B. S., Rother, K. I., Walter, M. F., Kushchayeva, Y. S., Auh, S., Shamburek, R. D., Remaley, A. T., Muniyappa, R., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa191 · Cited by 11
Novel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 13
Approach to the Patient With Moderate Hypertriglyceridemia
Subramanian, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac085 · Cited by 12
Familial chylomicronemia syndrome: importance of diagnostic vigilance
Ueda, M. (2022) · Translational Pediatrics · doi:10.21037/tp-22-488 · Cited by 12
Kelly, M. S., Beavers, C. J., Bucheit, J. D., Sisson, E. M., & Dixon, D. L. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.05.014 · Cited by 10
New and Future Parenteral Therapies for the Management of Lipid Disorders
García, R. R., & Burkle, J. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.01.001 · Cited by 10
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0771-8_5 · Cited by 10
Novel regulators of plasma lipid levels
Loaiza, N., Oldoni, F., & Kuivenhoven, J. A. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000416 · Cited by 10
Olivieri, O., Turcato, G., Moruzzi, S., Castagna, A., Girelli, D., Pizzolo, F., Friso, S., Sandri, M. F., Bassi, A., & Martinelli, N. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010973 · Cited by 10
Genetics of early-onset coronary artery disease
Lali, R., Cui, E., Ansarikaleibari, A., Pigeyre, M., & Paré, G. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000676 · Cited by 11
Tsushima, T., Tsushima, Y., Sullivan, C., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.12.011 · Cited by 9
A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
Kim, K., & Choi, S. H. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.250 · Cited by 11
Li, J., Sun, H., Wang, Y., Liu, J., & Wang, G. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01797-0 · Cited by 9
Phenome-wide Mendelian randomization study of plasma triglyceride levels and 2600 disease traits
Park, J. K., Bafna, S., Forrest, I. S., Duffy, Á., Márquez‐Luna, C., Petrazzini, B. O., Vy, H. M. T., Jordan, D. M., Verbanck, M., Narula, J., et al. (2023) · eLife · doi:10.7554/elife.80560 · Cited by 9
Thériault, S., Don-Wauchope, A., Chong, M., Lali, R., Morrison, K. M., & Paré, G. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.07.009 · Cited by 9
Insights from population-based analyses of plasma lipids across the allele frequency spectrum
Peloso, G. M., & Natarajan, P. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.01.003 · Cited by 10
Stroke Genomics: Current Knowledge, Clinical Applications and Future Possibilities
Appunni, S., Rubens, M., Ramamoorthy, V., Saxena, A., McGranaghan, P., & Veledar, E. (2022) · Brain Sciences · doi:10.3390/brainsci12030302 · Cited by 11
Cheng, Y., Li, T., Tan, P., Du, Y., Huang, Z., Shi, H., Cai, T., Chen, Y., & Fu, W. (2022) · Endocrine · doi:10.1007/s12020-022-03025-8 · Cited by 10
Toplak, H., Ludvik, B. H., Lechleitner, M., Dieplinger, H., Föger, B., Paulweber, B., Weber, T., Watschinger, B., Horn, S., Wascher, T. C., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0993-x · Cited by 9
Poststatin Lipid Therapeutics: A Review
Jia, X., Lorenz, P., & Ballantyne, C. M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-32 · Cited by 11
Biotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
Parhofer, K. G., Chapman, M. J., & Nordestgaard, B. G. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa116 · Cited by 11
Roychowdhury, T., Klarin, D. M., Levin, M. G., Spin, J. M., Rhee, Y. H., Deng, A. C., Headley, C. A., Surakka, I. L., Tsao, N. L., Gellatly, C., et al. (2022) · medRxiv · doi:10.1101/2022.05.27.22275607 · Cited by 9
Ference, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
Genetics of remnant cholesterol
Wulff, A. B., & Nordestgaard, B. G. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000991 · Cited by 8
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?
Biolo, M., Galimberti, F., Portinari, C., Bertocco, S., Tosin, P., Casula, M., Previato, L., Zambon, S., Simioni, P., & Zambon, A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01315-w · Cited by 9
Genetics for the Identification of Lipid Targets Beyond PCSK9
Wang, L. R., & Hegele, R. A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.11.003 · Cited by 8
Childhood Hypertriglyceridemia: Is It Time for a New Approach?
Sunil, B., & Ashraf, A. P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01000-2 · Cited by 9
Jacobsen, A. P., Whelton, S. P., Blumenthal, R. S., & McEvoy, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00042-6 · Cited by 13
Approach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 8
Targeted Delivery of Antisense Oligonucleotides Through Angiotensin Type 1 Receptor
Kuo, C., Nikan, M., Yeh, S. T., Chappell, A. E., Tanowitz, M., Seth, P. P., Prakash, T. P., & Mullick, A. E. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.0105 · Cited by 8
Dancer, M. S., Caussy, C., Filippo, M. D., Moulin, P., Marçais, C., & Charrière, S. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.024 · Cited by 9
Experimental Biology for the Identification of Causal Pathways in Atherosclerosis
Guo, Y., Garcia-Barrio, M. T., Wang, L., & Chen, Y. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6644-7 · Cited by 8
Olivieri, O., Cappellari, M., Turcato, G., Bonetti, B., Girelli, D., Pizzolo, F., Friso, S., Bassi, A., Castagna, A., & Martinelli, N. (2019) · Stroke · doi:10.1161/strokeaha.119.026811 · Cited by 8
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
Kosmas, C. E., Sourlas, A., Silverio, D., Montan, P. D., & Guzman, E. (2019) · World Journal of Cardiology · doi:10.4330/wjc.v11.i11.256 · Cited by 8
Xiao, Q., Wang, L., Wang, J., Wang, M., Wang, D. W., & Ding, H. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102011 · Cited by 8
The past, present and future of lipidlowering therapy
Najam, O., Lambert, G. C., & Ray, K. K. (2015) · Clinical Lipidology · doi:10.2217/clp.15.40 · Cited by 7
Clarifying complex inheritance: apolipoprotein C3 and atherosclerosis
Galton, D. J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000425 · Cited by 7
Assessing Rare Variation in Complex Traits
Kuchenbaecker, K. B., & Appel, E. V. R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7868-7_5 · Cited by 6
Watts, L. M., Karwatowska‐Prokopczuk, E., Hurh, E., Alexander, V. J., Balogh, K., O'Dea, L. S. L., Geary, R. S., & Tsimikas, S. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0837 · Cited by 7
Self-citationChétiveaux, M., Croyal, M., Ouguerram, K., Fall, F., Flet, L., Zaïr, Y., Nobécourt, E., & Krempf, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-72323-w · Cited by 7
Xu, Y., Guo, J., Zhang, L., Miao, G., Lai, P., Zhang, W., Liu, L., Hou, X., Wang, Y., Huang, W. Y., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.840358 · Cited by 7
Targeting triglycerides to lower residual cardiovascular risk
Bubb, K. J., Nelson, A. J., & Nicholls, S. J. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2058489 · Cited by 8
Hypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment
Wieczorek, E., Ćwiklińska, A., & Jankowski, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0189 · Cited by 7
Cardiovascular risk reduction: the future of cholesterol lowering drugs
Malham, S. B., & Goldberg, A. C. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.01.007 · Cited by 8
Mechanistic insights from combining genomics with metabolomics
Drenos, F. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000393 · Cited by 7
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 7
Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy
Brown, W. V. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1127 · Cited by 7
Emerging Strategies for the Management of Atherogenic Dyslipidaemia
Agarwala, A., & Shapiro, M. D. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.16 · Cited by 7
Twenty years of genome-wide association studies: Health translation challenges and AI opportunities
Huang, J., McLean, G. R., & Franke, A. (2025) · European Journal of Human Genetics · doi:10.1038/s41431-025-01951-5 · Cited by 10
Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review
Luca, C. D., Ciciola, P., D’Errico, G., Taranto, M. D. D., Fortunato, G., Gross, C., Garn, J., Iannuzzo, G., Minno, M. N. D. D., & Calcaterra, I. L. (2025) · Genes · doi:10.3390/genes16111377 · Cited by 7
Silencing ApoC3 alleviates LPS-induced acute lung injury by inhibiting TLR signaling pathway
Qi, Y., Chen, C., Li, X., Liu, Y., Qi, H., Xue, Y., & Yang, F. (2023) · Immunologic Research · doi:10.1007/s12026-023-09379-z · Cited by 6
Verbeek, R., Oldoni, F., Surendran, R. P., Zwinderman, A. H., Khaw, K., Stroes, E. S. G., Wareham, N. J., Boekholdt, S. M., & Dallinga‐Thie, G. M. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.02.005 · Cited by 6
Life is complicated: so is apoCIII
Reyes‐Soffer, G., & Ginsberg, H. N. (2019) · Journal of Lipid Research · doi:10.1194/jlr.c119000214 · Cited by 6
Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII
Recio-López, P., Valladolid‐Acebes, I., Hadwiger, P., Hoßbach, M., Krampert, M., Prata, C. A. H., Berggren, P., & Juntti‐Berggren, L. (2022) · BioFactors · doi:10.1002/biof.1885 · Cited by 6
Genetics-based risk scores for prediction of premature coronary artery disease
Gupta, R. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.08.003 · Cited by 7
Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?
Lechner, K., Kessler, T., & Schunkert, H. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01408-9 · Cited by 6
Wadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70005 · Cited by 6
Tsioulos, G., Vallianou, N. G., Skourtis, A., Dalamaga, Μ., Kotsi, E., Kargioti, S., Adamidis, N., Karampela, Ι., Mourouzis, I. S., & Kounatidis, D. C. (2024) · Biomolecules · doi:10.3390/biom14121637 · Cited by 6
Drug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome: Focus on Volnesorsen
Gesner, M., & Frishman, W. H. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000468 · Cited by 5
Update on management of paediatric dyslipidaemia
Bansal, N., Kumar, S., & Brar, P. C. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000794 · Cited by 4
Posicionamento Brasileiro sobre Síndrome da Quilomicronemia Familiar – 2023
Izar, M. C. D. O., Santos, R. D., Assad, M. H. V., Chagas, A. C. P., Toledo, A. D. O., Nogueira, A. C. C., Souto, A. C. C. F., Lottenberg, A. M., Chacra, A. P. M., Ferreira, C. E. D. S., et al. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230203 · Cited by 7
Chukwurah, M. I., & Miller, M. J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01926-2 · Cited by 5
Lipid clinical trials with special reference to Indian population
Aseem Basha, M., & Ramakrishnan, S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.02.003 · Cited by 5
The Essence of Lipoproteins in Cardiovascular Health and Diseases Treated by Photodynamic Therapy
Wańczura, P. M., Aebisher, D., Iwański, M. A., Myśliwiec, A., Dynarowicz, K., & Bartusik‐Aebisher, D. (2024) · Biomedicines · doi:10.3390/biomedicines12050961 · Cited by 5
Nicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 6
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
Genomic Strategies Toward Identification of Novel Therapeutic Targets
Kessler, T., & Schunkert, H. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_360 · Cited by 5
Corbin, L. J., Hughes, D. A., Chetwynd, A. J., Taylor, A. E., Southam, A. D., Jankevics, A., Weber, R. J. M., Groom, A., Dunn, W. B., & Timpson, N. J. (2020) · Metabolomics · doi:10.1007/s11306-020-01689-9 · Cited by 5
New therapeutic approaches for the treatment of hypertriglyceridemia
Gouni‐Berthold, I., & Schwarz, J. (2022) · Herz · doi:10.1007/s00059-022-05113-x · Cited by 6
Metadata
- Authors
- Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., Crooke, R. M., Witztum, J. L., Brunzell, J. D., & Kastelein, J. J. P.
- Affiliations
- University of Washington (US)
- Ionis Pharmaceuticals (United States) (US)
- Université de Montréal (CA)
- University of California San Diego (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-30
- Volume
- 373
- Issue
- 5
- Pages
- 438-447
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2315899065
- Semantic Scholar
- b8b4f0ae969760d3373ca1d9082abfee85fe16d9
- Cited by
- 528
- References
- 51
- Citations by year
- 2026: 23 · 2025: 28 · 2024: 27 · 2023: 32 · 2022: 51 · 2021: 46 · 2020: 63 · 2019: 61 · 2018: 68 · 2017: 58 · 2016: 58 · 2015: 13
- FWCI
- 47.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, antisense oligonucleotides, hypertriglyceridemia, triglyceride lowering, fibrate therapy, dose-ranging, cardiovascular risk, pancreatitis risk, triglyceride metabolism, monotherapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Cholesterol, HDL, Male, Middle Aged, Oligonucleotides, Triglycerides, Hypertriglyceridemia, Apolipoprotein C-III, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
